Metabolic syndrome, inflammation and lower urinary tract symptoms: Possible translational links

Prostate Cancer and Prostatic Diseases

Volumn 19, Issue 1, 2016, Pages 7-13

  He, Q ^a,b   Wang, Z ^b   Liu, G ^c   Daneshgari, F ^c   MacLennan, G T ^a   Gupta, S ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LANZHOU UNIVERSITY   (China)

^c METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER OBSTRUCTION; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; FACTUAL DATABASE; HUMAN; INFLAMMATION; LOWER URINARY TRACT SYMPTOM; METABOLIC SYNDROME X; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; URINE INCONTINENCE; BLADDER; LOWER URINARY TRACT SYMPTOMS; MALE; PATHOLOGY; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

HUMANS; INFLAMMATION; LOWER URINARY TRACT SYMPTOMS; MALE; METABOLIC SYNDROME X; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; URINARY BLADDER;

EID: 84957850419     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2015.43     Document Type: Review

References (81)

1. King D. The future challenge of obesity. Lancet 2011; 378: 743-744.
2. Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
3. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009; 94: 1853-1878.
4. Després J-P, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887.
5. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
6. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2595-2600.
7. Donnell RF. Benign prostate hyperplasia: a review of the year's progress from bench to clinic. Curr Opin Urol 2011; 21: 22-26.
8. Moul S, McVary KT. Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr Opin Urol 2010; 20: 7-12.
9. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-178.
10. Nickel J. Prostatic inflammation in benign prostatic hyperplasia-the third component? Can J Urol 1994; 1: 1-4.
11. Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology 2002; 59: 245-250.
12. Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, De Nunzio C et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int 2015; 115: 24-31.
13. De Nunzio C, Cindolo L, Gacci M, Pellegrini F, Carini M, Lombardo R et al. Metabolic syndrome and lower urinary tract symptoms in patients with benign prostatic enlargement: a possible link to storage symptoms. Urology 2014; 84: 1181-1187.
14. Bhindi B, Margel D, Trottier G, Hamilton RJ, Kulkarni GS, Hersey KM et al. Obesity is associated with larger prostate volume but not with worse urinary symptoms: analysis of a large multiethnic cohort. Urology 2014; 83: 81-87.
15. Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol 2013; 189: S102-S106.
16. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761.
17. Kasturi S, Russell S, McVary KT. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Prostate Rep 2006; 4: 127-131.
18. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007; 51: 199-206.
19. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011; 60: 106-117.
20. Bunn F, Kirby M, Pinkney E, Cardozo L, Chapple C, Chester K et al. Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies. Int J Clin Pract 2014; 69: 199-217.
21. Tai H-C, Chung S-D, Ho C-H, Tai T-Y, Yang W-S, Tseng C-H et al. Metabolic syndrome components worsen lower urinary tract symptoms in women with type 2 diabetes. J Clin Endocrinol Metab 2010; 95: 1143-1150.
22. Uzun H, Zorba OÜ. Metabolic syndrome in female patients with overactive bladder. Urology 2012; 79: 72-75.
23. Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 2009; 20: 182.
24. Fagerberg B, Behre CJ, Wikstrand J, Hultén LM, Hulthe J. C-reactive protein and tumor necrosis factor-alpha in relation to insulin-mediated glucose uptake, smoking and atherosclerosis. Scand J Clin Lab Inves 2008; 68: 534-541.
25. Greenfield JR, Campbell LV. Relationship between inflammation, insulin resistance and type 2 diabetes:'cause or effect'? Curr Diabetes Rev 2006; 2: 195-211.
26. Powell K. Obesity: the two faces of fat. Nature 2007; 447: 525-527.
27. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 2010; 33: 475-488.
28. Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007; 14: 226-234.
29. Penna G, Mondaini N, Amuchastegui S, Degli Innocenti S, Carini M, Giubilei G et al. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol 2007; 51: 524-533.
30. Lotti F, Maggi M. Interleukin 8 and the male genital tract. J reprod Immunol 2013; 100: 54-65.
31. Hochreiter WW, Nadler RB, Koch AE, Campbell PL, Ludwig M, Weidner W et al. Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. Urology 2000; 56: 1025-1029.
32. Liu L, Li Q, Han P, Li X, Zeng H, Zhu Y et al. Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia. Urology 2009; 74: 340-344.
33. Lotti F, Corona G, Vignozzi L, Rossi M, Maseroli E, Cipriani S et al. Metabolic syndrome and prostate abnormalities in male subjects of infertile couples. Asian J Androl 2014; 16: 295.
34. Lotti F, Corona G, Vitale P, Maseroli E, Rossi M, Fino M et al. Current smoking is associated with lower seminal vesicles and ejaculate volume, despite higher testosterone levels, in male subjects of infertile couples. Hum Reprod 2015; 30: 590-602.
35. Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F, Laverny G et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol 2009; 182: 4056-4064.
36. Adorini L, Penna G, Fibbi B, Maggi M. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. Ann NY Acad Sci 2010; 1193: 146-152.
37. Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E et al. The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kB pathways. Prostate 2009; 69: 480-493.
38. Giri D, Ittmann M. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 2001; 159: 139-147.
39. Gharaee-Kermani M, Kasina S, Moore BB, Thomas D, Mehra R, Macoska JA. CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PLoS One 2012; 7: e49278.
40. Shankar E, Vykhovanets EV, Vykhovanets OV, MacLennan GT, Singh R, Bhaskaran N et al. High-fat diet activates pro-inflammatory response in the prostate through association of Stat-3 and NF-?B. Prostate 2012; 72: 233-243.
41. Vykhovanets EV, Shankar E, Vykhovanets OV, Shukla S, Gupta S. High-fat diet increases NF-?B signaling in the prostate of reporter mice. Prostate 2011; 71: 147-156.
42. Vignozzi L, Filippi S, Comeglio P, Cellai I, Morelli A, Maneschi E et al. Tadalafil Effect on Metabolic Syndrome-Associated Bladder Alterations: An Experimental Study in a Rabbit Model. J Sex Med 2014; 11: 1159-1172.
43. Morelli A, Sarchielli E, Comeglio P, Filippi S, Vignozzi L, Marini M et al. Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits. Mol Cell Endocrinol 2014; 382: 107-119.
44. Robert G, Descazeaud A, Nicolaiëw N, Terry S, Sirab N, Vacherot F et al. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate 2009; 69: 1774-1780.
45. Delongchamps NB, de la Roza G, Chandan V, Jones R, Sunheimer R, Threatte G et al. Evaluation of prostatitis in autopsied prostates-is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 2008; 179: 1736-1740.
46. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-2398.
47. Nickel J, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999; 84: 976-981.
48. Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M et al. Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. Eur Urol 2014; 66: 619-622.
49. Kwon YK, Choe MS, Seo KW, Park CH, Chang HS, Kim BH et al. The effect of intraprostatic chronic inflammation on benign prostatic hyperplasia treatment. Korean J Urol 2010; 51: 266-270.
50. Mishra VC, Allen DJ, Nicolaou C, Sharif H, Hudd C, Karim O et al. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 2007; 100: 327-331.
51. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 2008; 54: 1379-1384.
52. Cantiello F, Cicione A, Salonia A, Autorino R, Tucci L, Madeo I et al. Periurethral fibrosis secondary to prostatic inflammation causing lower urinary tract symptoms: a prospective cohort study. Urology 2013; 81: 1018-1024.
53. Stewart W, Van Rooyen J, Cundiff G, Abrams P, Herzog A, Corey R et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-336.
54. Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des 2008; 14: 1225-1230.
55. Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-? signaling in fibrosis. Growth Factors 2011; 29: 196-202.
56. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011; 7: 684-696.
57. Rodriguez-Nieves JA, Macoska JA. Prostatic fibrosis, lower urinary tract symptoms, and BPH. Nat Rev Urol 2013; 10: 546-550.
58. Kuo H-C, Liu H-T, Shie J-H. Potential urine and serum biomarkers for patients with overactive bladder and interstitial cystitis/bladder pain syndrome. Tzu Chi Med J 2013; 25: 13-18.
59. Hsiao S-M, Lin H-H, Kuo H-C. The role of serum C-reactive protein in women with lower urinary tract symptoms. Int Urogynecol J 2012; 23: 935-940.
60. Tyagi P, Barclay D, Zamora R, Yoshimura N, Peters K, Vodovotz Y et al. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol 2010; 42: 629-635.
61. Chung SD, Liu HT, Lin H, Kuo HC. Elevation of serum c-reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder. Neurourol Urodyn 2011; 30: 417-420.
62. Lenis AT, Kuang M, Woo LL, Hijaz A, Penn MS, Butler RS et al. Impact of parturition on chemokine homing factor expression in the vaginal distention model of stress urinary incontinence. J Urol 2013; 189: 1588-1594.
63. Chen H-Y, Lin Y-N, Chen Y-H, Chen W-C. Stress urinary incontinence following vaginal trauma involves remodeling of urethral connective tissue in female mice. Eur J Obstet Gynecol Reprod Biol 2012; 163: 224-229.
64. Chen H-Y, Chen C-J, Lin Y-N, Chen Y-H, Chen W-C, Chen C-M. Proteomic analysis related to stress urinary incontinence following vaginal trauma in female mice. Eur J Obstet Gynecol Reprod Biol 2013; 171: 171-179.
65. Juan YS, Chuang SM, Lee YL, Long CY, Wu TH, Chang WC et al. Green tea catechins decrease oxidative stress in surgical menopause-induced overactive bladder in a rat model. BJU Int 2012; 110: E236-E244.
66. Wang L-w, Han X-m, Chen C-h, Ma Y, Hai B. Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder. Int Urol Nephrol 2014; 46: 341-347.
67. Agilli M, Aydin FN, Kurt YG, Cayci T. A potential biomarker for objective diagnosis of overactive bladder: urinary nerve growth factor. Int Urol Nephrol 2014; 47: 317-318.
68. Bhide AA, Cartwright R, Khullar V, Digesu GA. Biomarkers in overactive bladder. Int Urogynecol J 2013; 24: 1065-1072.
69. Dallosso H, McGrother C, Matthews RJ, Donaldson M. The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women. BJU Int 2003; 92: 69-77.
70. Link CL, Steers WD, Kusek JW, McKinlay JB. The association of adiposity and overactive bladder appears to differ by gender: results from the Boston Area Community Health survey. J Urol 2011; 185: 955-963.
71. He Q, Wang H, Yue Z, Yang L, Tian J, Liu G et al. Waist circumference and risk of lower urinary tract symptoms: a meta-analysis. Aging Male 2014; 17: 223-229.
72. Tsai Y-C, Liu C-H. Urinary incontinence among Taiwanese women: an outpatient study of prevalence, comorbidity, risk factors, and quality of life. Int Urol Nephrol 2009; 41: 795-803.
73. Uzun H, Yilmaz A, Kemik A, Zorba OU, Kalkan M. Association of insulin resistance with overactive bladder in female patients. Int Neurourol J 2012; 16: 181-186.
74. Sutcliffe S, Giovannucci E, De Marzo AM, Willett WC, Platz EA. Sexually transmitted infections, prostatitis, ejaculation frequency, and the odds of lower urinary tract symptoms. Am J Epidemiol 2005; 162: 898-906.
75. Krieger JN, Lee SWH, Jeon J, Cheah PY, Liong ML, Riley DE. Epidemiology of prostatitis. Int J Antimicrob Agents 2008; 31: 85-90.
76. Colodner R, Eliasberg T, Chazan B, Raz R. Clinical significance of bacteriuria with low colony counts of Enterococcus species. Eur J Clin Microbiol Infect Dis 2006; 25: 238-241.
77. Lee S, Yang G, Bushman W. Prostatic inflammation induces urinary frequency in adult mice. PLoS One 2015; 10: e0116827.
78. Steigedal M, Marstad A, Haug M, Damås JK, Strong RK, Roberts PL et al. Lipocalin 2 Imparts Selective Pressure on Bacterial Growth in the Bladder and Is Elevated in Women with Urinary Tract Infection. J Immunol 2014; 193: 6081-6089.
79. Eynard AR, Navarro A. Crosstalk among dietary polyunsaturated fatty acids, urolithiasis, chronic inflammation, and urinary tract tumor risk. Nutrition 2013; 29: 930-938.
80. Jou Y-C, Tsai Y-S, Fang C-Y, Chen S-Y, Chen F-H, Huang C-H et al. Mass Spectrometric Study of Stone Matrix Proteins of Human Bladder Stones. Urology 2013; 82: 295-300.
81. Keddis MT, Rule AD. Nephrolithiasis and loss of kidney function. Curr Opin Nephrol Hypertens 2013; 22: 390.